Business Context and Reporting Period
This Form 8-K Current Report was filed by Harvard Bioscience, Inc. on January 28, 2022, covering events occurring on January 24, 2022. The filing primarily addresses the resignation of a senior executive and the execution of a related separation agreement.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on corporate governance and personnel changes.
Material Changes
- Executive Departure: Ken Olson resigned as Chief Operating Officer (COO) effective January 31, 2022, citing personal reasons.
- Transition Period: Mr. Olson will remain employed until December 31, 2022, providing remote assistance and facilitating the transition of COO duties.
- Agreement Execution: A Separation Agreement and Release was entered into on January 26, 2022, ensuring continued salary payment through the transition period.
Guidance, Outlook, and Risks
The filing states that Mr. Olson's resignation was not the result of any disagreement regarding the Company's operations, policies, or practices. No financial guidance, outlook, or new risk factors were disclosed in this report. The full terms of the separation are detailed in the attached Exhibit 10.1.
Investor Verification Checklist
- Verify the terms of the Separation Agreement (Exhibit 10.1) for any severance payments or equity vesting acceleration beyond the stated salary continuation.
- Monitor subsequent filings for the appointment of a permanent or interim replacement for the Chief Operating Officer role.
- Review the Company's next quarterly report (10-Q) to assess any operational impact resulting from the leadership transition.